The Mast Therapeutics, Inc. (SVRA) Shares Down 10.3%

The Mast Therapeutics, Inc. (SVRA)  Shares Down 10.3%

Mast Therapeutics, Inc. (NASDAQ:SVRA) was down 10.3% during mid-day trading on Wednesday . The company traded as low as $7.85 and last traded at $8.26. Approximately 806,913 shares traded hands during mid-day trading, an increase of 795% from the average daily volume of 90,158 shares. The stock had previously closed at $9.21.

A number of equities research analysts have recently issued reports on SVRA shares. Roth Capital reiterated a “buy” rating and issued a $40.00 target price on shares of Mast Therapeutics in a research note on Wednesday, September 27th. Jefferies Group LLC started coverage on Mast Therapeutics in a research note on Friday, September 22nd. They issued a “buy” rating and a $20.00 target price for the company. Zacks Investment Research upgraded Mast Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research note on Tuesday, September 19th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $18.00 target price on shares of Mast Therapeutics in a research note on Monday, July 17th. Five research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $21.50.

The firm’s market capitalization is $199.92 million. The firm’s 50 day moving average price is $8.79 and its 200 day moving average price is $6.70.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Related posts

Leave a Comment